Vor Biopharma Analyst Price Targets - Benzinga

Vor Biopharma Inc

VORNASDAQ

Trade with Public

Trade with Public

$20.05

0.924.81%

Dern. MÀJ: Oct 9, 1:39 PM

$19.67

0.542.82%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Vor Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vor Biopharma (VOR).

Price Target Range — 11 Quarters

Analyst Consensus — 12 Analysts

10Buy

2Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$62Upside to Avg. PT+207.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 12, 2026	Wedbush	Martin Fan	PT Raise	Neutral	$18→$27
May 18, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$31
May 14, 2026	Wedbush	Martin Fan	PT Raise	Neutral	$15→$18
Apr 15, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$32→$31
Mar 31, 2026	Wedbush	Martin Fan	PT Raise	Neutral	$9→$15
Mar 30, 2026	Jefferies	Farzin Haque	Initiate	Buy	$50
Mar 19, 2026	Wells Fargo	Sadia Rahman	Initiate	Overweight	$30
Jan 9, 2026	Citigroup	Geoff Meacham	Initiate	Buy	$50
Dec 19, 2025	JP Morgan	Anupam Rama	PT Cut	Overweight	$43→$40
Dec 17, 2025	TD Cowen	Yaron Werber	Initiate	Buy	—
Dec 9, 2025	JP Morgan	Anupam Rama	Initiate	Overweight	$43
Nov 25, 2025	Wedbush	Martin Fan	Assumes	Neutral	$9
Nov 14, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$55→$32
Oct 29, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$3→$55
Oct 15, 2025	Baird	Jack Allen	Upgrade	Neutral→Outperform	$20→$64
Aug 14, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$3
Jun 30, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Upgrade	Neutral→Buy	$3
Jun 27, 2025	Baird	Jack Allen	PT Raise	Neutral	$0→$1
Jun 26, 2025	Wedbush	David Nierengarten	Maintained	Neutral	$0
May 9, 2025	JMP Securities	Silvan Tuerkcan	Downgrade	Market Outperform→Market Perform	$6

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $31 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vor Biopharma (NASDAQ:VOR) with a Buy and maintains $31 price target.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $15 to $18.

Benzinga Newsdesk

Microsoft To $500? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and upgrades/downgrades on our analyst ratings page.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Vor Biopharma, Lowers Price Target to $31

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vor Biopharma (NASDAQ:VOR) with a Buy and lowers the price target from $32 to $31.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $15

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $9 to $15.

Benzinga Newsdesk